Therapeutic Goods Administration (TGA)

The Therapeutic Goods Administration (TGA) is Australia’s national regulatory authority responsible for regulating medicines, medical devices, vaccines, biological products, and other therapeutic goods. Established in 1989 and headquartered in Canberra, Australia, TGA operates as part of the Australian Government Department of Health and Aged Care.

TGA ensures that therapeutic products available in Australia meet strict standards for safety, quality, and effectiveness. The organization evaluates and monitors prescription medicines, over-the-counter medicines, vaccines, blood products, medical devices, diagnostic technologies, and complementary medicines.

The agency performs regulatory activities including product approvals, clinical trial oversight, manufacturing inspections, Good Manufacturing Practice (GMP) certification, pharmacovigilance monitoring, and post-market safety surveillance.

TGA works closely with pharmaceutical companies, biotechnology organizations, medical device manufacturers, healthcare professionals, researchers, and international regulatory authorities. It provides scientific guidance to support healthcare innovation while maintaining strong patient protection standards.

The organization plays an important role in regulating advanced healthcare technologies, including biological therapies, cell and gene therapies, personalized medicines, and emerging medical technologies.

TGA participates in global regulatory cooperation programs and works with organizations such as the U.S. FDA, EMA, PMDA, and ICH to improve international healthcare regulation standards.

Through evidence-based scientific assessment and continuous monitoring, TGA helps ensure Australians have access to safe and effective therapeutic products while supporting innovation within the healthcare industry.